Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 15, 1998
Issued Date -
N/A
app pub date -
Nov 28, 1995
filing date -
Nov 29, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
A method of preventing renal failure or dysfunction caused by medical tests which utilize contrast media by administering, preferably by intravenous infusion or injection, a prostaglandin selected from PGE.sub.1, PGE.sub.2, PGI.sub.2 or an analog or pharmaceutically acceptable salt thereof and preferably in a form of a complex with .alpha.-cyclodextrin, to a patient at risk, for example, a diabetic.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully